SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...

The authors examine the role of Numb, a Notch inhibitor, in intestinal stem cell self-renewal in Drosophila during homeostasis and regeneration. This is an important study providing evidence of a Numb ...

Michigan State landed linebacker Aisea Moa, a former BYU four-star recruit from Utah, in the transfer portal. Moa's younger brother, Salesi, is one of the top prospects in the 2026 class.

CSPC Pharmaceutical Group Ltd. on Jan. 13 gained the National Medical Products Administration’s approval of Shanzeping (prusogliptin tablets; DBPR-108) as a novel oral dipeptidyl peptidase-IV (DPP-4) ...

The DPP holds only 28 seats. Japan's first lower house election since 2021 took place as Ishiba's conservative Liberal Democratic Party faced intense scrutiny over revelations that some of its ...

"We found that the addition of SGLT2 inhibitors as an add-on therapy was associated with a higher risk of amputations, stent placements, or revascularization surgeries compared to DPP-4 inhibitors.," ...